IMPDH1
ENSG00000106348
Target class
Enzyme
Chromosome
7
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- Yes
- Target name
- IMPDH1
- Gene name
- Inosine monophosphate dehydrogenase 1
- Gene symbol
- IMPDH1
- Previous gene symbols
- RP10
- Protein name
- Inosine-5'-monophosphate dehydrogenase 1 (IMP dehydrogenase 1) (IMPD 1) (IMPDH 1) (EC 1.1.1.205) (IMPDH-I)
- sWSS2608
- LCA11
- Gene biotype
- Protein coding
- Gene family
- Inosine monophosphate dehydrogenase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 172.5
- Tissue specificity (Gini)
- 0.332
- Tissue specificity (tau)
- 0.786
- KEGG gene identifiers
- hsa:3614
- Protein interaction confidence
- 0.849188
- Protein interaction partners
- 64
- R-HSA-6798695
- R-HSA-73817
- R-HSA-9679191
- R-HSA-9748787
- End position
- 128410009
- Start position
- 128392277
- Chromosome
- 7
- Strand
- Reverse
- Cytoplasm . Nucleus .
- Cytosol
- Rods & Rings
Publication evidence
- PubMed 14766016
- Tissue specificity (tau)
- 0.785647
- Expression inequality (Gini)
- 0.332335
Expression in transcripts per million
- Whole Blood
- 172.5
- Spleen
- 95.56
- Cells - Cultured fibroblasts
- 82.82
- Adipose - Visceral (Omentum)
- 79.9
- Adipose - Subcutaneous
- 66.89
Expression in transcripts per million
- Whole Blood172.5
- Spleen95.56
- Cells - Cultured fibroblasts82.82
- Adipose - Visceral (Omentum)79.9
- Adipose - Subcutaneous66.89
- Lung65.86
- Nerve - Tibial63.23
- Breast - Mammary Tissue60.8
- Stomach57.24
- Prostate56.32
- Bladder52.46
- Pituitary51.99
- Cervix - Endocervix48.81
- Ovary46.66
- Artery - Coronary46.32
- Minor Salivary Gland45.46
- Artery - Aorta45.24
- Vagina43.62
- Esophagus - Muscularis42.62
- Skin - Sun Exposed (Lower leg)42.35
- Esophagus - Gastroesophageal Junction42.09
- Fallopian Tube41.82
- Colon - Sigmoid41.71
- Cervix - Ectocervix41.32
- Testis39.68
And 29 more, listed on the interactive page.
- GO:0005576
- GO:0005634
- GO:0005737
- GO:0005829
- GO:0034774
- GO:0035578
- GO:1904813
- GO:0003676
- GO:0003677
- GO:0003938
Related records
Trials (2,861)
- 1.Comparison of the Analgesic Effect of Remifentanil Group and Different Dose Groups of Oliceridine in Postoperative Patients Undergoing Cardiac Surgery 2.Exploring the Hemodynamic Effects of Analgesic Regimens With Different Doses of Oliceridine After Cardiac Surgery
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients
- 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF
- 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
- 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- 24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients
- 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
- 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
- 36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILI
- 48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection
- 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)
- 5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)
- 5-HTP and Creatine for Depression R33 Phase
- 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
- 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
- A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
- A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
- A Bioequivalence Study to Compare VIMOVO Manufactured at AstraZenca AB to VIMOVO Manufactured by Patheon Pharmaceuticals and Marketed Enteric-coated Naproxen Formulation
Drugs (9)
- AVN-944 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Merimepodib Inosine-5'-monophosphate dehydrogenase 1 inhibitor
- Mizoribine Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Mycophenolate mofetil Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Mycophenolate mofetil hydrochloride Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Mycophenolate sodium Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Mycophenolic acid Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- Ribavirin Inosine-5'-monophosphate dehydrogenase 1 inhibitor
- Thioguanine Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor